Australian tertiary care outcomes of entecavir monotherapy in treatment naive patients with chronic hepatitis B

doi:10.3748/wjg.v19.i5.721

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 19, Issue 5

This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5785)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

527

HTML

2933

Figures (1-2)

206

Tables (1-3)

203

Sum=3869

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1077

Download

839

Sum=1916

Feb 7, 2013 (publication date) through Nov 23, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Feb 7, 2013; 19(5): 721-726
Published online Feb 7, 2013. doi: 10.3748/wjg.v19.i5.721

Table 1 Baseline demographics (n = 163) n (%)

Age (yr)
Mean age	52.0 (24-86)
Mean age at start	47.4 (20-81)
Gender
Males	113 (69.3)
Females	50 (30.7)
Pre-treatment Biopsies	134 (82.2)
Duration of therapy (mo)
Range	3-46
Mean	25.63
Median	23
Patients > 24 mo	79 (48.5)
Patients > 36 mo	49 (30.1)
Co-infection
Hepatitis C	1 (0.61)
HBV DNA load (IU/mL)
> 100 000	95 (58.3)
2000-100 000	45 (27.6)
12-2000	23 (14.1)
HBe antigen status	41 (25.2)
e antigen positive	112 (68.7)
e antigen negative	10 (6.1)
Unknown
ALT (U/L)
10-40	39 (23.9)
40-400	118 (72.4)
> 400	5 (3.01)
Unknown	1 (0.61)
Fibrosis score	0-10 (6.13)
135 (82.82%)	1-61 (37. 4)
	2-38 (23.3)
	3-17 (10.4)
	4-9 (5.52)
	Unknown-27 (16.6)

HBV: Hepatitis B virus; ALT: Alanine aminotransferase.

Table 2 Follow up of DNA values and cumulative rates of complete and partial virological suppression n (%)

Month	0	6	12	18	24	30	36	42
Patients with DNA	163 (100)	158 (96.9)	141 (86.5)	121 (74.2)	105 (64.4)	76 (46.6)	56 (34.4)	24 (14.7)
Complete virological suppression	0/169 (0)	104/158 (65.8)	117/141 (83.0 )	96/121 (74.4)	94/105 (89.5)	65/76 (85.5)	46/56 (82.1)	19/24 (79.2)
Cumulative CVS	0%	66.7%	88.8%	85.1%	94.8%	93.2%	92.2%	91.6%
Partial virological suppression	22/163 (13.5)	141/158 (89.2)	133/141 (94.3)	117/121 (90.7)	100/105 (95.2)	75/76 (98.7)	54/56 (96.4)	23/24 (95.8)
Cumulative PVS	13.5%	89.2%	94.9%	92.1%	96.3%	99.0%	97.3%	96.6%

CVS: Complete virological suppression; PVS: Partial virological suppression.

Table 3 Complete virological suppression based on age and HBeAg status

Age-log rank 0.001 (median)
< 40 yr-	40-55 yr-	> 55 yr-
12 mo (9.25-14.75)	6 mo (5.01-6.99)	6 mo (5.24-6.76)
Hepatitis B e antigen negative status-log rank 0.19 (median)
< 40 yr-	40-55 yr-	> 55 yr-
6 mo (4.05-7.95)	6 mo (4.99-7.02)	6 mo (5.59-6.41)
Hepatitis B e antigen positive status-log rank 0.19 (median)
< 40 yr-	40-55 yr-	> 55 yr-
18 mo (7.37-28.63)	18 mo (14.17-26.47)	6 mo (6.5-17.5)
Hepatitis B e antigen seroconversion rate based on age-log rank 0.559 (median)
< 40 yr-	40-55 yr-	> 55 yr-
36 mo (20.55-51.45)	30 mo (18.46-41.54)	6 mo (9.8-32.2)

Citation: Fahrtash-Bahin F, Kariyawasam VC, Gray T, Byth K, George J, Douglas MW. Australian tertiary care outcomes of entecavir monotherapy in treatment naive patients with chronic hepatitis B. World J Gastroenterol 2013; 19(5): 721-726
URL: https://www.wjgnet.com/1007-9327/full/v19/i5/721.htm
DOI: https://dx.doi.org/10.3748/wjg.v19.i5.721